In a number of severe and acute diseases such as stroke, neurotrauma, circulatory shock, and acute myocardial infarction, activation of PARP-1 is detectable in human tissue samples supporting the clinical application of PARP-1 inhibition [14–16]. This evidence concerns the gene PARP1 and Shock.